Comparative analysis of serum antibody responses to Pseudomonas aeruginosa exotoxin A by cystic fibrosis and intensive care unit patients.

1983 ◽  
Vol 18 (3) ◽  
pp. 457-462 ◽  
Author(s):  
G Cukor ◽  
N R Blacklow ◽  
N A Nowak ◽  
C M Rich ◽  
L E Braverman ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Comparative Analysis ◽  
Serum Antibody ◽  
Antibody Responses ◽  
Exotoxin A ◽  
Pseudomonas Aeruginosa Exotoxin

scholarly journals Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients

2004 ◽  
Vol 48 (9) ◽  
pp. 3573-3575 ◽  
Author(s):  
Olivia Gutiérrez ◽  
Carlos Juan ◽  
José L. Pérez ◽  
Antonio Oliver
Keyword(s):  
Cystic Fibrosis ◽  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Antibiotic Resistance ◽  
Intensive Care ◽  
Large Collection ◽  
Resistance Development ◽  
Icu Patients

ABSTRACT Hypermutation is a common feature of Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients that is linked with antibiotic resistance development. In this work, using a large collection of sequential P. aeruginosa isolates from ICU patients, we found that despite the fact that mutational antibiotic resistance development is a frequent outcome, the prevalence of hypermutable strains is low (found in isolates from only 1 of 103 patients) and there is no evidence of coselection of the hypermutable and antibiotic resistance phenotypes.

scholarly journals Creation of a Combination Antibiogram for Pseudomonas aeruginosa in a Pediatric Intensive Care Unit

2021 ◽  
Vol 26 (8) ◽  
pp. 828-833
Author(s):  
R. Zachary Thompson ◽  
Cheryl L. Sargel ◽  
Melissa Moore-Clingenpeel ◽  
Todd J. Karsies
Keyword(s):  
Cystic Fibrosis ◽  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Susceptibility Pattern ◽  
First Line ◽  
Resistance Rates ◽  
Antimicrobial Regimen

OBJECTIVE This study describes the creation of a combination antibiogram directed toward Pseudomonas aeruginosa to determine the most appropriate empiric antimicrobial regimen(s). METHODS P aeruginosa isolates were collected from all sites between January 2013 and December 2017 for patients admitted to the PICU. Patients with cystic fibrosis and isolates from the same site and susceptibility pattern obtained within 30 days were excluded. β-Lactam susceptibilities were determined and compared with the addition of an aminoglycoside or fluroquinolone and summarized in a combination antibiogram. RESULTS One hundred ninety-nine P aeruginosa isolates were included for analysis. The addition of a second agent to piperacillin-tazobactam was shown to have the most significant improvement among the β-lactams, with 70% susceptibility as monotherapy and increases to above 90% with the addition of an aminoglycoside or fluroquinolone. The addition of an aminoglycoside or fluroquinolone to cefepime and meropenem increased coverage to above 95%. The addition of a second agent was likely to increase susceptibility of a monotherapy backbone; however, as the susceptibility of the first-line agent decreased, the susceptibility of the second agent needed to be higher to achieve a 95% coverage threshold. CONCLUSIONS Our results support use of a second agent to significantly improve the likelihood of appropriate empiric coverage of P aeruginosa. Use of a combination antibiogram may be more beneficial than a simple antibiogram for units with increasing resistance rates, or for coverage of specific resistant organisms.

Sign in / Sign up

Export Citation Format

Share Document